New England Journal of Medicine· 2016Q1
Adalimumab in Patients with Active Noninfectious Uveitis
- 664citations
- Q1SCImago
- 2016year
Short summary
Adalimumab significantly reduced the risk of treatment failure in patients with active noninfectious uveitis, with a median time to failure of 24 weeks compared to 13 weeks for placebo (HR 0.50, P<0.001).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Ophthalmology
OphthalmologyMedicine